Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01

Sep 9, 2024

Press releases

Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01

Evaxion announces new exciting clinical phase 2 data for its lead compound EVX-01.
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Sep 9, 2024

Press releases

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Evaxion announces new pre-clinical data demonstrating the ability of its novel EVX-B2 mRNA Gonorrhea vaccine candidate in eliminating gonorrhea bacteria by triggering a targeted immune response.
Company Presentation

Sep 5, 2024

Company Presentation

Company Presentation

Are you eager to deep-dive into Evaxion's business? Download our company presentation.

Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes

Sep 2, 2024

Publications

Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes

Publication: Nature Communications
Authors: Asolina Braun, Louise C. Rowntree, Ziyi Huang, Kirti Pandey, Nikolas Thuesen, Chen Li, Jan Petersen, Dene R. Littler, Shabana Raji, Thi H. O. Nguyen, Emma Jappe Lange, Gry Persson, Michael Schantz Klausen, Jens Kringelum, Shanzou Chung, Nathan P. Croft, Pouya Faridi, Rochelle Ayala, Jamie Rossjohn, Patricia T. Illing, Katherine E. Scull, Sri Ramarathinam, Nicole A. Mifsud, Katherine Kedzierska, Anders Bundgård Sørensen & Anthony W. Purcell

Benchmarking NGS-Based HLA Typing Algorithms

Aug 21, 2024

Publications

Benchmarking NGS-Based HLA Typing Algorithms

Publication: Springer Protocols
Authors: Nikolas Thuesen and Michael Schantz Klausen

Evaxion Announces Business Update and Second Quarter 2024 Financial Results

Aug 14, 2024

Press releases

Evaxion Announces Business Update and Second Quarter 2024 Financial Results

Evaxion provides business update and announces second quarter 2024 financial results.
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Aug 12, 2024

Press releases

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Evaxion will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM.
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

Aug 8, 2024

Press releases

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

Evaxion is proud to announce the presentation of one-year clinical efficacy Phase 2 data for its lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain, from September 13-17, 2024.
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Jul 16, 2024

Press releases

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Evaxion today showcases improved performance of its key building block, EvaxMHC, within its AI-Immunology™ platform, at the 32nd Intelligent Systems for Molecular Biology (ISMB) conference taking place in Montreal, Canada, from July 12-16, 2024.
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

Jul 3, 2024

Press releases

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

Evaxion today issued the following letter to shareholders.
The Big Biz Show Interview with Evaxion's CEO Christian Kanstrup

Jul 1, 2024

Other Presentations

The Big Biz Show Interview with Evaxion's CEO Christian Kanstrup

In this interview, Bob "Sully" Sullivan and Mike Costa from the Big Biz Show interview our CEO, Christian Kanstrup, about Evaxion's Innovative AI-Immnuology™ platform, personalized cancer vaccines, and market projections.

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Jun 26, 2024

Press releases

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Evaxion receives positive feedback on its recent patent application for a new type of personalized vaccine targets, underscoring its novelty and inventiveness.